AnaptysBio announced an exclusive license agreement for Centessa Pharmaceuticals’ blood dendritic cell antigen 2, or BDCA2, modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases. Anaptys anticipates filing an IND application for CBS004, which will be renamed ANB101, in H2 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANAB:
- Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
- Anaptys Named a BioSpace 2024 Best Places to Work Winner
- AnaptysBio price target raised to $20 from $18 at Wedbush
- AnaptysBio reports Q3 collaboration revenue $3.3M vs. $1.3M last year
- Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
